cancer vaccine - EpiVax, Inc. - Informatics and Immunology

Tumor homology with self as a biomarker for response to checkpoint inhibitor therapy

by Corey Iacono | Nov 17, 2022

EpiVaxTx_SITC22_Melanoma_28Oct22_56Wx31.5H

Multi-step screening of neoantigens’ HLA- and TCR-interfaces improves prediction of survival

by Riley Nolan | May 13, 2021

Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models

by Annie De Groot | Aug 2, 2019

Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models

Computational Identification of Self-Like Neoantigens Enables the Rapid Design of Immunogenic Cancer Vaccines

by Annie De Groot | Apr 8, 2019

EpiVax_Oncology_TRI-CON_CT26_04Mar19_32w44h

Ancer-designed CT26 RNA Replicon Neo-epitope Vaccine Induces Multi-functional CD4 and CD8 T Cell Responses

by Annie De Groot | Oct 5, 2018

EpiVax_ISV2018_CT26_01Oct18_50Wx36H

Tumor homology with self as a biomarker for response to checkpoint inhibitor therapy

Multi-step screening of neoantigens’ HLA- and TCR-interfaces improves prediction of survival

Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models

Computational Identification of Self-Like Neoantigens Enables the Rapid Design of Immunogenic Cancer Vaccines

Ancer-designed CT26 RNA Replicon Neo-epitope Vaccine Induces Multi-functional CD4 and CD8 T Cell Responses

Recent Posts

Categories